Skip to main content
. 2018 Aug 31;9(68):32885–32899. doi: 10.18632/oncotarget.25972

Figure 1. ATO has relatively selective anti-proliferative effects against FLT3/ITD + leukemia cells.

Figure 1

A. FLT3/ITD+ (Molm14, MV4;11), FLT3/WT (THP1) or FLT3 negative cells (U937) were treated with ATO for up to 72 hours. Cells were subjected to MTT-based cell proliferation assays. B. IC50 was calculated based on the MTT assay results at 48 hours.